Surprisingly, even GBM patients with differences in O6-methyl-guanine-DNA methyltransferase methylation status (MGMT) showed a measurable and common immune signature, enough to classify MGMT status with 0% cross validation error. The gene discussed is MGMT; the disease is glioblastoma.